Moderna began a medical trial to review the security and effectiveness of a booster shot that particularly targets the omicron Covid variant, the corporate introduced Wednesday.

The primary participant within the section two trial has already obtained a dose of the omicron-specific booster shot, in line with the corporate.

Moderna expects to enroll about 600 grownup contributors ages 18 and over break up between two teams. Members within the first group may have beforehand obtained two-doses of Moderna’s authentic vaccine, and contributors within the second group may have beforehand obtained the corporate’s presently approved booster shot.

Moderna additionally printed information on how its 50 microgram booster shot is holding up towards omicron. Six months after the third shot, the antibodies that block omicron an infection declined, however they nonetheless remained detectable in all contributors. The info signifies that whereas the booster weakens over time, it nonetheless gives some safety towards the variant.

The neutralizing antibodies triggered by Moderna’s current booster declined quicker when pitted towards omicron, 6.3 fold, in contrast with a decline of about 2.3 fold towards the unique pressure of the virus over the identical time interval.

CEO Stephane Bancel stated Moderna is reassured the neutralizing antibodies towards omicron stay detectable after half a yr.

“Nonetheless, given the long-term menace demonstrated by Omicron’s immune escape, we’re advancing our Omicron-specific variant vaccine booster candidate,” Bancel stated.

Bancel beforehand stated he expected the efficacy of booster doses would seemingly declined over time.

Pfizer and BioNTech stated they began testing their omicron-specific vaccine on folks earlier this week, enrolling 1,420 contributors ages 18 to 55. The businesses anticipate to have the photographs prepared by March.